Literature DB >> 9637732

Isolation, sequence analysis, and biological activity of atrolysin E/D, the non-RGD disintegrin domain from Crotalus atrox venom.

K Shimokawa1, L G Jia, J D Shannon, J W Fox.   

Abstract

Crotalid snake venom metalloproteinases often have associated with them nonproteinase domains that may be processed from the mature proteinases. Nascent atrolysin E, from the western diamondback rattlesnake, Crotalus atrox, has a metalloproteinasedomain and a non-RGD disintegrin domain that is lacking in the mature metalloproteinase. In this studywe report on the isolation, sequence analysis, andbiological activity of the 7.4-kDa atrolysin E disintegrin domain (atrolysin E/D). Atrolysin E/D represents approximately 0.2% of the total protein fromthe crude venom. The protein begins with a glycinyl residue found in the latter part of the spacer region. The sequence of atrolysin E/D is identical to thatof the non-RGD disintegrin domain of atrolysin E. The structure is termed a non-RGD disintegrin sincein lieu of the characteristic RGD sequence, a Met-Val-Asp (MVD) is found instead. Nevertheless, the protein is a potent inhibitor of both collagen- and ADP-stimulated platelet aggregation with IC50 values of 4 and 8 nM, respectively. A cyclized synthetic peptide, Ac-CRVSMVDRNDDTC-NH2, which represents the sequence of the atrolysin E/D non-RGD loop, was demonstrated to be an effective inhibitor of platelet aggregation. Therefore, this region of atrolysin E/D's structure, as in the disintegrins proper, is important for the biological activity of the protein. Thus, like the non-RGD disintegrin barbourin from Sistrurus miliarius barbouri, a RGD sequence in the context of the disintegrin protein backbone is not an absolute requirement for platelet aggregation inhibitory activity. These data underscore the biochemical and functional complexity of crotalid snake venoms due to differential proteolytic processing of the precursor metalloproteinases and exemplify how the processed fragments may contribute to the observed pathological effects of the venom. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637732     DOI: 10.1006/abbi.1998.0698

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Purification, molecular cloning and mechanism of action of graminelysin I, a snake-venom-derived metalloproteinase that induces apoptosis of human endothelial cells.

Authors:  W B Wu; S C Chang; M Y Liau; T F Huang
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

2.  The disulfide bond pattern of catrocollastatin C, a disintegrin-like/cysteine-rich protein isolated from Crotalus atrox venom.

Authors:  J J Calvete; M P Moreno-Murciano; L Sanz; M Jürgens; M Schrader; M Raida; D C Benjamin; J W Fox
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

3.  Recombinant rubistatin (r-Rub), an MVD disintegrin, inhibits cell migration and proliferation, and is a strong apoptotic inducer of the human melanoma cell line SK-Mel-28.

Authors:  Clayton M Carey; Raymund Bueno; Daniel A Gutierrez; Christopher Petro; Sara E Lucena; Elda E Sanchez; Julio G Soto
Journal:  Toxicon       Date:  2011-12-13       Impact factor: 3.033

4.  Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering.

Authors:  Juan J Calvete; M Paz Moreno-Murciano; R David G Theakston; Dariusz G Kisiel; Cezary Marcinkiewicz
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

5.  Amino acid sequence and homology modeling of obtustatin, a novel non-RGD-containing short disintegrin isolated from the venom of Vipera lebetina obtusa.

Authors:  M Paz Moreno-Murciano; Daniel Monleón; Juan J Calvete; Bernardo Celda; Cezary Marcinkiewicz
Journal:  Protein Sci       Date:  2003-02       Impact factor: 6.725

Review 6.  Exogenous Integrin αIIbβ3 Inhibitors Revisited: Past, Present and Future Applications.

Authors:  Danique L van den Kerkhof; Paola E J van der Meijden; Tilman M Hackeng; Ingrid Dijkgraaf
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.